Radiopharm Theranostics RADX
NASDAQ RADX
$2.15 +0.09 (+4.36%)
As of: Sep 10, 2026 · 10:29 AM EDT

Radiopharm Theranostics Ltd (RADX) EBITDA Margin (2024 - 2026)

Radiopharm Theranostics' (RADX) quarterly EBITDA Margin came in at 291.35% in Q2 2026, up 5606064.0% year-over-year from N/an in Q2 2025, and up 99.48% quarter-over-quarter from 56351.99% in Q2 2025.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Radiopharm Theranostics Ltd (RADX) EBITDA Margin (2024 - 2026) Analysis & Trends

Radiopharm Theranostics (RADX) has reported EBITDA Margin for 3 consecutive years, with 291.35% the latest figure, recorded in Q2 2026.

Peer Set

Peer Comparison

All peers
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -291.35%
Jun 30, 2025 -56,351.99%
Jun 30, 2024 -109.14%